Parker et al. suggested that nilotinib synergizes with MEK inhibitors to kill drug-resistant CML cells, and blocks tumor growth in mice [27]. The gene discussed is MAP2K7; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.